Search Results 611-620 of 16057 for pharmacogenetics

1. Overview - Knowledge and Evaluation Research Unit - Mayo Clinic Research

   The Knowledge and Evaluation Research Unit at Mayo Clinic was founded by Victor Montori, M.D., to promote evidence-based, patient-centered care and shared ...

2. Petrice M. Cogswell, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

   2019. FellowRST Neuroradiology, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine · 2018. Residency - Radiology ...

3. News - Translational Cell Biology of Parkinson's Disease Laboratory - Mayo Clinic Research

   Read news from Dr. Springer's Translational Cell Biology of Parkinson's Disease Lab at Mayo Clinic highlighting gene studies in Parkinson's disease.

4. Drugs and Supplements that Start with M - Mayo Clinic

   Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “M” to learn about drug side effects, proper use and ...

5. Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism - Mayo Clinic

   This study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

6. A Study of SGN-B7H4V in Advanced Solid Tumors - Mayo Clinic

   A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near where it started ...

7. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of ZB131 in patients with solid tumors where prevalence of CSP ...

8. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   The purpose of this study is to assess the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose ...

9. Development of PARP Inhibitors and DDR Modifiers To Treat Ovarian Cancer - Anticancer Drug Action Laboratory - Mayo Clinic Research

   Dr. Kaufmann and his team in the Anticancer Drug Action Lab at Mayo Clinic are studying the susceptibility of HR-deficient cancer cells to PARP inhibitors ...

10. Publications - Bruce D. Johnson, Ph.D. - Mayo Clinic

    ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations. Pharmacogenomics. 2020 Jul; 21 (10):695-703 Epub 2020 June 05. View ...